FDA Approves ZYNLONTA — ADC Therapeutics America, Inc.

# FDA Approves ADC Therapeutics' ZYNLONTA for Relapsed or Refractory Diffuse Large B-Cell Lymphoma ADC Therapeutics America, Inc. received FDA approval for ZYNLONTA (loncastuximab tesirine), an antibody-drug conjugate marking the company's first commercial product and potentially capturing significant market share in the estimated $4+ billion lymphoma treatment space. The intravenous therapy's approval positions ADC Therapeutics to compete directly with established players in oncology while opening additional pipeline opportunities for its targeted cancer platform.